Buscar resultados de ensayos clínicos
Anaplastic Large Cell Lymphoma - 340 Studies Found
Estado | Estudiar |
Active, not recruiting |
Nombre del estudio: ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas Condición:
Intervenciones: |
Active, not recruiting |
Nombre del estudio: Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL Condición:
|
Completed |
Nombre del estudio: Sorafenib in Treating Patients With Recurrent Non-Hodgkin's Lymphoma Condición:
|
Active, not recruiting |
Nombre del estudio: A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma Condición:
|
Recruiting |
Nombre del estudio: Risk Stratification of Nodal PTCL Condición:
Fecha: 2017-01-31 |
Recruiting |
Nombre del estudio: Brentuximab Vedotin in High-Risk CD30+ Lymphoma Post Allogeneic Stem Cell Transplantation (AlloSCT) Condición: Lymphoma Fecha: 2014-06-11 Intervenciones: Drug: Brentuximab Vedotin Starting dose: 1.2 mg/kg by vein on Day 1 for the first 2, 21 day cycles. Dose |
Recruiting |
Nombre del estudio: Brentuximab Vedotin for Relapsed/Refractory CD30-positive Non-Hodgkin Lymphomas Condición: Non-Hodgkin Lymphoma Fecha: 2014-10-05 Intervenciones: Drug: Brentuximab vedotin Brentuximab vedotin must not be administered as an IV push or bolus. It must b |
Available |
Nombre del estudio: A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001 Condición:
|
Active, not recruiting |
Nombre del estudio: A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms Condición:
|
Active, not recruiting |
Nombre del estudio: Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma Condición:
|